No Data
BeiGene Shares Are Trading Lower. The Company Reported Q3 Financial Results.
beigene's Q3 single-quarter revenue exceeded 1 billion US dollars. Will the two lawsuits with AbbVie affect future revenue?
①Beigene achieved product revenue of 7.079 billion yuan in the third quarter, with a total quarterly revenue of 7.139 billion yuan, and a revenue of 1.002 billion US dollars under the US GAAP, exceeding 1 billion US dollars in a single quarter for the first time. ②Excluding non-cash items such as share-based payment expenses, depreciation and amortization expenses, Beigene's adjusted operating profit for the third quarter was 65.63 million US dollars.
BeiGene Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPADS and Sales.
BeiGene GAAP EPADS of -$1.15 Misses by $0.16, Revenue of $1B Beats by $15.76M
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Historically the most 'competitive'? The Tenth Batch of National Procurement Pharmaceutical Catalog Is Officially Announced with one type having up to 31 companies competing.
①This afternoon, the National Pharmaceutical Joint Procurement Office officially announced the tenth batch of nationally purchased pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Several industry insiders have stated that the tenth batch of national procurement will be the largest and most competitive national procurement in history.